BRISBANE, Calif., Sept. 14 /PRNewswire/ — SARcode Corporation,
a privately-held biotechnology company focused on developing a
novel class of lymphocyte function-associated antigen-1 (LFA-1)
antagonists, today announced that Quinton Oswald has joined the
company as Chief Executive Officer.
Mr. Oswald brings significant commercial experience and
management expertise to the CEO role. Most recently at Genentech,
where he served as the Vice President & Business Unit Head for
the Tissue Growth and Repair Business, Mr. Oswald was responsible
for four key franchises – Ophthalmology, Growth Hormone,
Fibrinolytics and Cystic Fibrosis – generating over $2.1
billion in annual sales. During his tenure at Genentech, Mr. Oswald
oversaw the successful commercial launch of Lucentis®
(ranibizumab) in 2006, the third fastest new product introduction
in U.S. pharma history. Lucentis® was approved for the
treatment of neovascular (wet) age-related macular degeneration
(AMD) and reached sales of over $1 billion in 2009. This
breakthrough therapy dramatically changed the treatment paradigm
for retinal specialists by offering their patients the ability to
stabilize and improve vision, instead of facing a progressive
course toward blindness.
Prior to Genentech, Mr. Oswald led the North American
Ophthalmology business for Novartis, which in conjunction with QLT,
Inc. pioneered Visudyne® (verteporfin), the first drug
treatment for wet AMD. Launched in 2000, Visudyne® replaced
thermal laser therapy, offering a more targeted and less damaging
treatment to slow vision decline.
“We are very pleased to have Quinton join our team at SARcode,”
said Robert Alexander, Director at Alta Partners and member of the
SARcode Board of Directors. “He brings the right combination of
sector knowledge and commercial expertise needed to lead SARcode
through Phase III trials and on to the market. Quinton is a perfect
fit for this role, given his long
‘/>”/>
